ロード中...
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for investigating its use in combination with other agents. Vitamin K2 is nearly non-toxic to humans and has been shown to inhib...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3438252/ https://ncbi.nlm.nih.gov/pubmed/23018309 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6061/clinics/2012(09)18 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|